10 June 2021 - Purdue Pharma announced that FDA has accepted and granted priority review to the company’s abbreviated new drug application for the vial dosage form of nalmefene hydrochloride injection.
FDA previously granted competitive generic therapy designation for the vial and pre-filled syringe and fast track designation for the auto-injector.